1 Definition and function
C3 convertase is a proteolytic enzyme complex of the complement system that cleaves complement component C3 into the fragments C3a and C3b. This reaction is a central amplification step in innate immunity. By generating C3b on a target surface, the convertase helps tag microbes, immune complexes, and damaged cells for recognition and removal by phagocytes.
1.1 Role in the complement system
The complement system consists of soluble proteins and membrane-associated regulators that cooperate to detect danger and promote immune defense. C3 convertase occupies a key position in this network because it links the early recognition stages of complement activation to the broader effector functions that follow. Once formed, it rapidly increases the number of active complement molecules at or near a target surface.
1.2 Catalytic cleavage of C3
C3 is one of the most abundant proteins in blood plasma. C3 convertase cleaves a single internal peptide bond in C3, producing C3a and C3b. C3a is released as a small signaling fragment, while C3b exposes a reactive thioester group that can attach covalently to nearby surfaces. This surface attachment is essential for the localization of complement activity.
1.3 Biological effects of C3 activation
The products of C3 cleavage have several immune effects. C3b promotes opsonization, making targets easier for phagocytes to ingest. C3a contributes to inflammatory signaling and can influence local vascular and immune responses. Continued deposition of C3b also supports formation of later complement enzyme complexes, extending the cascade toward the membrane attack pathway.
2 Formation of C3 convertase
C3 convertase is not a single fixed enzyme but a family of related complexes assembled through distinct complement pathways. Each pathway uses different recognition proteins, yet they converge on a common enzymatic function. The resulting convertases are short-lived and tightly controlled, reflecting the need for powerful but localized complement activation.
2.1 Classical pathway convertase
The classical pathway is triggered when complement recognition components interact with immune complexes or other activating surfaces. Its convertase is built from fragments of C4 and C2, forming the complex C4b2a.
2.1.1 C4 and C2 activation
After pathway initiation, C4 is cleaved to C4a and C4b. C4b binds to the activating surface and provides a platform for the next protein, C2. C2 is then cleaved, allowing formation of the enzymatic complex. This sequence positions catalytic activity close to the target surface.
2.1.2 Assembly of C4b2a
When C2 is cleaved on surface-bound C4b, the larger fragment remains associated and yields the active convertase C4b2a. This complex functions efficiently as a C3-cleaving enzyme in the classical pathway and is also used by the lectin pathway. Its activity is localized by the surface attachment of C4b.
2.2 Lectin pathway convertase
The lectin pathway begins with recognition of carbohydrate patterns on microbial surfaces. Although its initiation differs from that of the classical pathway, the enzymatic convertase formed is the same C4b2a complex.
2.2.1 Mannose-binding lectin and MASPs
Mannose-binding lectin and related lectins recognize specific sugar motifs. Once bound, they activate associated serine proteases known as MASPs. These proteases cleave C4 and C2 in a manner analogous to the classical pathway, initiating convertase assembly without antibodies.
2.2.2 Assembly of C4b2a in the lectin pathway
The downstream steps mirror those of the classical pathway. C4b deposited on the surface binds C2, which is then processed to create the active C4b2a complex. This shared convertase explains the close functional relationship between the classical and lectin pathways.
2.3 Alternative pathway convertase
The alternative pathway generates a distinct C3 convertase, C3bBb. It operates through continuous low-level activation of C3 and can amplify complement activity on surfaces that favor stable C3b deposition.
2.3.1 Spontaneous C3 activation
C3 undergoes a low-rate spontaneous conformational change known as tickover, producing forms that can participate in complement activation. When this process occurs in the presence of a permissive surface, C3b is generated and can initiate alternative pathway assembly. This mechanism allows rapid sensing of non-self or altered self surfaces.
2.3.2 Assembly of C3bBb
Surface-bound C3b binds factor B, which is then cleaved by factor D. The resulting Bb fragment stays attached to C3b, creating the active convertase C3bBb. This complex is functionally important because it can both cleave more C3 and reinforce its own pathway.
2.3.3 Properdin stabilization
Properdin is a positive regulator that stabilizes the alternative pathway convertase. By prolonging the lifetime of C3bBb, it enhances C3 cleavage and increases complement deposition. This stabilization helps sustain complement activity on activating surfaces.
3 Structure and molecular composition
C3 convertases are multi-protein assemblies whose composition determines both specificity and stability. Although the classical/lectin and alternative pathway convertases differ in subunit makeup, they share the same broad enzymatic role. Their function depends on transient interactions among catalytic and surface-binding components.
3.1 Subunit components
The classical and lectin pathway convertase contains C4b and the activated fragment of C2. The alternative pathway convertase contains C3b and Bb, the enzymatic portion of factor B. In both cases, one component provides surface anchoring, while the other supplies protease activity.
3.2 Enzymatic active site
The active site resides in the protease component of the convertase, where substrate recognition and cleavage occur. In C4b2a, the protease function is associated with the C2-derived fragment. In C3bBb, it is carried by Bb. The active site is oriented so that bound C3 can be cleaved efficiently.
3.3 Membrane-associated vs fluid-phase forms
Most biologically important convertase activity occurs on cell or particle surfaces. Surface binding increases efficiency and limits unintended cleavage in plasma. Fluid-phase convertase-like activity can occur transiently, but it is usually short-lived and rapidly inactivated by regulatory proteins.
4 Regulation of C3 convertase
Because C3 convertase can strongly amplify complement activation, it is tightly regulated. Control mechanisms limit its lifespan, restrict its activity to appropriate surfaces, and prevent damage to host tissues. These regulatory steps are essential for maintaining immune balance.
4.1 Decay acceleration
Decay acceleration refers to the dissociation of convertase subunits. Several complement regulators promote the release of the protease-containing fragment from the surface-bound component. This process reduces enzymatic activity and prevents prolonged complement activation.
4.2 Cofactor-mediated inactivation
C3b can be rendered inactive by proteolytic cleavage when an appropriate cofactor is present. This inactivation reduces the ability of C3b to participate in further convertase formation. By limiting the pool of active C3b, the system curbs self-amplification.
4.3 Complement control proteins
A group of soluble and membrane-bound proteins supervises convertase activity. These proteins work through decay acceleration, cofactor support, or both. Their combined action helps distinguish host surfaces from activating targets.
4.3.1 Factor H
Factor H is a soluble regulator of the alternative pathway. It preferentially associates with host-like surfaces and helps limit C3bBb formation. Factor H also acts as a cofactor for the inactivation of C3b, making it a major safeguard against excessive alternative pathway activity.
4.3.2 Factor I
Factor I is a protease that cleaves C3b and related fragments only in the presence of cofactors. By processing C3b into inactive derivatives, it prevents persistent convertase assembly. Its function depends on cooperation with molecules such as factor H and membrane cofactors.
4.3.3 DAF and MCP
Decay-accelerating factor and membrane cofactor protein are host cell surface regulators. DAF promotes dissociation of convertase components, whereas MCP assists factor I-mediated inactivation of C3b. Together, they help protect self cells from complement-mediated injury.
5 Role in complement amplification
C3 convertase is central to the amplification phase of complement activation. Once formed, it generates large amounts of C3b, which can support further convertase formation. This positive-feedback behavior allows a limited initiating signal to expand into a robust immune response.
5.1 Positive feedback in the alternative pathway
The alternative pathway is especially dependent on amplification. New C3b molecules can bind factor B and generate additional C3bBb complexes. This creates a self-reinforcing cycle that intensifies complement activity at activating surfaces.
5.2 Generation of additional C3b
Each convertase molecule can cleave many C3 molecules over its lifetime. The resulting C3b can deposit near the original activation site and broaden the area of complement labeling. This accumulation improves opsonization and increases the likelihood of downstream complement activation.
5.3 Formation of downstream convertases
C3b generated by the convertase also contributes to the assembly of later complement enzymes. In the classical and lectin pathways, additional C3b can help form C5 convertase. In the alternative pathway, added C3b shifts the complex toward C5-cleaving activity as well. This progression links C3 activation to terminal complement events.
6 Clinical significance
Altered C3 convertase activity can have important medical consequences. Deficiency, instability, or excessive activation may impair host defense or contribute to tissue injury. As a result, convertase components and regulators are of interest in diagnosis and therapy.
6.1 Complement deficiencies
Inherited defects in pathway components can reduce C3 convertase formation and weaken complement function. Such deficiencies may lead to increased susceptibility to certain infections. Defects in regulatory proteins can also disturb control of the convertase and alter complement balance.
6.2 Overactivation in disease
Excessive convertase activity can increase complement deposition on host tissues. Unchecked amplification may contribute to inflammatory damage and hemolysis in selected disorders. In many cases, the underlying problem involves impaired regulation rather than the convertase proteins alone.
6.3 Therapeutic targeting
Because of its central position in complement activation, the convertase and its regulators are targets for therapeutic intervention. Strategies may aim to reduce convertase formation, shorten its lifetime, or block downstream amplification. Such approaches are designed to preserve useful immune function while limiting harmful overactivation.
7 Experimental study and laboratory assays
C3 convertase has been studied through functional assays, biochemical reconstruction, and structural methods. These approaches help define how the complex assembles, how long it remains active, and how regulators affect its behavior. Experimental analysis has been essential for mapping pathway-specific differences.
7.1 Functional complement assays
Laboratory assays can measure the ability of serum or purified components to cleave C3 or support complement activation on defined surfaces. These tests provide information about pathway integrity and regulatory capacity. They are often used to assess complement function in research and clinical settings.
7.2 Reconstitution and biochemical analysis
Purified proteins can be combined in controlled systems to rebuild convertase complexes. Reconstitution experiments allow investigators to identify the minimal components required for activity and to analyze kinetic properties. Biochemical methods also clarify how cofactors and inhibitors influence assembly and decay.
7.3 Structural biology approaches
Structural studies, including crystallography and related methods, have helped reveal how convertase subunits fit together. These approaches show how catalytic fragments align with surface-bound components and how regulators interfere with complex stability. Such information has improved understanding of both enzyme function and therapeutic design.